Literature DB >> 18704007

Novel potential therapies for septic shock.

Luciano Cesar Pontes Azevedo, Marcelo Park, Guilherme Paula Pinto Schettino.   

Abstract

Sepsis is the systemic inflammatory response syndrome secondary to a local infection. Septic shock, the severe complication of sepsis associated with refractory hypotension, is frequently a near-fatal condition requiring prompt diagnosis and management. Although the recent years have been associated with considerable improvements in the knowledge of the pathophysiology of the disease and remarkable advances have been achieved in sepsis treatment, the morbidity and mortality of this disease are still unacceptably high. In this review, we will briefly discuss the ongoing standard treatment of septic shock and describe novel potential therapies, aiming to improve hemodynamic support and/or control inflammatory response in sepsis. These therapies were associated with benefits in experimental studies and have been tested or are currently under testing in randomized controlled studies with septic patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18704007     DOI: 10.1097/SHK.0b013e318181a425

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  5 in total

Review 1.  Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients.

Authors:  Arturo J Martí-Carvajal; Ivan Solà; Christian Gluud; Dimitrios Lathyris; Andrés Felipe Cardona
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

2.  Induction of endothelium-dependent constriction of mesenteric arteries in endotoxemic hypotensive shock.

Authors:  Tzu-Ling Tseng; Mei-Fang Chen; Chin-Hung Liu; Cheng-Yoong Pang; Yung-Hsiang Hsu; Tony J F Lee
Journal:  Br J Pharmacol       Date:  2016-03-06       Impact factor: 8.739

3.  High-volume hemofiltration in adult burn patients with septic shock and acute kidney injury: a multicenter randomized controlled trial.

Authors:  Kevin K Chung; Elsa C Coates; David J Smith; Rachel A Karlnoski; William L Hickerson; Angela L Arnold-Ross; Michael J Mosier; Marcia Halerz; Amy M Sprague; Robert F Mullins; Daniel M Caruso; Marlene Albrecht; Brett D Arnoldo; Agnes M Burris; Sandra L Taylor; Steven E Wolf
Journal:  Crit Care       Date:  2017-11-25       Impact factor: 9.097

4.  BRG1 Links TLR4 Trans-Activation to LPS-Induced SREBP1a Expression and Liver Injury.

Authors:  Wenhui Dong; Yuwen Zhu; Yangxi Zhang; Zhiwen Fan; Ziyu Zhang; Xiangshan Fan; Yong Xu
Journal:  Front Cell Dev Biol       Date:  2021-03-18

Review 5.  Use of Intravenous Immunoglobulins in Sepsis Therapy-A Clinical View.

Authors:  Dominik Jarczak; Stefan Kluge; Axel Nierhaus
Journal:  Int J Mol Sci       Date:  2020-08-03       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.